Boehringer Ingelheim registers Phase I mass balance trial for BI 3034701
Single-dose study tracks absorption and excretion of radiolabeled BI 3034701 in healthy men, listed July 16, 2026.
Boehringer Ingelheim had one trial update posted this week, a Phase I pharmacokinetics study.
- BI 3034701 (C-14), a radiolabeled investigational drug, is being tested in a Phase I single-dose trial in healthy men of normal weight or overweight. The trial is listed as active not recruiting, with an actual start date of 2026-08-24 and estimated primary completion on 2026-10-141. The study enrolled 8 participants and uses a single subcutaneous dose administered to a single arm1. Its main goal is to assess mass balance, meaning total recovery of radioactivity in urine, faeces, and expired air, after the single dose1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.